Molecular psychiatry
-
Molecular psychiatry · Jun 2015
Randomized Controlled TrialEstradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.
Many women with schizophrenia remain symptomatic despite optimal use of current therapies. While previous studies suggest that adjunctive oestrogen therapy might be effective, large-scale clinical trials are required before clinical applications are possible. This study is the first large-scale randomized-controlled trial in women with treatment-resistant schizophrenia. ⋯ Both estradiol groups had greater decreases in PANSS positive, general and total symptoms compared with the placebo group (P<0.01), with a greater effect seen for 200 μg than 100 μg estradiol. The largest effect size was for the positive subscale of PANSS in the estradiol 200 μg treatment group (effect size 0.44, P<0.01). This study shows estradiol is an effective and clinically significant adjunctive therapy for women with treatment-resistant schizophrenia, particularly for positive symptoms.
-
Molecular psychiatry · Jun 2015
Editorial Historical ArticleMolecular Psychiatry: Twenty years of progress from bench to clinic.